奥沙利铂联合替吉奥治疗晚期胃癌的疗效及对血清REGⅣ、CK18、VEGF、CEA和CA19-9水平的影响

Clinical effect of oxaliplatin combined with S-1 on patients with advanced gastric cancer and the impact on serum levels of REGIV, CK18, VEGF, CEA and CA19-9

目的探讨奥沙利铂联合替吉奥治疗晚期胃癌的疗效及对血清再生基因蛋白Ⅳ(REGⅣ)、细胞角蛋白18(CK18)、血管内皮细胞生长因子(VEGF)、癌胚抗原(CEA)及糖类抗原19-9(CA19-9)水平的影响。方法选取晚期胃癌患者98例,采用随机数字表法将患者随机分为研究组和对照组,每组49例。研究组患者接受奥沙利铂联合替吉奥治疗,对照组患者接受奥沙利铂、5-氟尿嘧啶、亚叶酸钙联合治疗。观察两组患者的近期疗效,并对两组患者的血清REGⅣ、CK18、VEGF、CEA及CA19-9水平进行比较。结果研究组患者的治疗有效率和疾病控制率均高于对照组,但差异均无统计学意义(P﹥0.05);治疗前,研究组和对照组患者的血清REGⅣ、CK18、VEGF、CEA及CA19-9水平比较,差异均无统计学意义(P﹥0.05);治疗后,研究组患者的血清REGⅣ、CK18、VEGF、CEA及CA19-9水平均低于对照组(P﹤0.05);治疗后,两组患者的血清REGⅣ、CK18、VEGF、CEA及CA19-9水平均较本组治疗前降低(P﹤0.05);研究组患者恶心呕吐、骨髓抑制的发生率均低于对照组(P﹤0.05);两组患者腹泻、皮疹、脱发、肝功能不全、肾功能不全的发生率比较,差异均无统计学意义(P﹥0.05)。结论奥沙利铂联合替吉奥治疗晚期胃癌的疗效可靠,能够进一步降低患者的血清REGⅣ、CK18、VEGF及CA19-9水平,且具有较好的耐受性。

Objective To investigate the curative effect of oxaliplatin combined with S-1on advanced gastric cancer and its effect on the serum levels of regenerating gene protein IV(REGIV),cytokeratin18(CK18),vascular endothelial growth factor(VEGF),carcinoembryonic antigen(CEA)and carbohydrate antigen19-9(CA19-9).Method A total of98patients with advanced gastric cancer were enrolled and randomly divided into study group and control group,49cases in each group.Patients in study group received oxaliplatin combined with S-1treatment and patients in control group received combination treatment of oxaliplatin,fluorouracil and leucovorin.The short-term clinical efficacy were observed and the serum levels of REGIV,CK18,VEGF,CEA and CA19-9of two groups were compared.Result The effective rate and disease control rate of study group were higher than those of control group,but without significant difference between the two groups(P>0.05).Before treatment,there were no significant difference in serum levels of REGIV,CK18,VEGF,CEA and CA19-9between the study group and the control group(P>0.05);after treatment,the serum levels of REGIV,CK18,VEGF,CEA and CA19-9of study group were significantly lower than those of control group(P<0.05);and after treatment,the serum levels of REGIV,CK18,VEGF,CEA and CA19-9in both two groups were significantly decreased compared to those before treatment(P<0.05).The incidences of nausea,vomiting and myelosuppression in study group were significantly lower than those in control group(P<0.05).There was no significant difference between the two groups of patients in the incidences of diarrhea,skin rash,alopecia,liver insufficiency and renal insufficiency(P>0.05).Conclusion The effect of oxaliplatin combined with S-1on the treatment for patients with advanced gastric cancer is reliable,which can further reduce the serum levels of REGIV,CK18,VEGF,CEA and CA19-9and be well tolerated.